Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/1/2026

1. NKE
2. TSLA
3. BE
4. SPY
5. NVDA
6. STZ
7. ABVX
8. MU
9. INTC
10. NOW

Go back to Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
Johnson & Johnson (NYSE: JNJ) Delayed: 252.37 -1.6 (0.63%)
Previous Close $253.97    52 Week High $126.07 
Open $253.25    52 Week Low $94.28 
Day High $254.20    P/E 52.47 
Day Low $251.08    EPS $4.81 
Volume 1,394,125